Advances in T Cell-Based Cancer Immunotherapy: From Fundamental Mechanisms to Clinical Prospects
Molecular Pharmaceutics · 2025
DOI: 10.1021/acs.molpharmaceut.4c01502 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Kaili Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Pharmacology, Tianjin Medical University Cancer Institute and Hospital; National Clinical Research Center for Cancer; Key Lab…. Hauptthemen laut MEDLINE: Neoplasms, Immunotherapy, Adoptive, T-Lymphocytes, Immunotherapy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 282 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Nankai University Eye Institute, Natural Science Foundation of Tianjin.
Abstract (Originalsprache)
T cells and their T cell receptors (TCRs) play crucial roles in the adaptive immune system's response against pathogens and tumors. However, immunosenescence, characterized by declining T cell function and quantity with age, significantly impairs antitumor immunity. Recent years have witnessed remarkable progress in T cell-based cancer treatments, driven by a deeper understanding of T cell biology and innovative screening technologies. This review comprehensively examines T cell maturation mechanisms, T cell-mediated antitumor responses, and the implications of thymic involution on T cell diversity and cancer prognosis. We discuss recent advances in adoptive T cell therapies, including tumor-infiltrating lymphocyte (TIL) therapy, engineered T cell receptor (TCR-T) therapy, and chimeric antigen receptor T cell (CAR-T) therapy. Notably, we highlight emerging DNA-encoded library technologies in mammalian cells for high-throughput screening of TCR-antigen interactions, which are revolutionizing the discovery of novel tumor antigens and optimization of TCR affinity. The review also explores strategies to overcome challenges in the solid tumor microenvironment and emerging approaches to enhance the efficacy of T cell therapy. As our understanding of T cell biology deepens and screening technologies advances, T cell-based immunotherapies show increasing promise for delivering durable clinical benefits to a broader patient population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Pharmacology, Tianjin Medical University Cancer Institute and Hospital; National Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical…
- School of Medicine, Nankai University, Tianjin 300071, China.
- Cell Biotechnology Laboratory, Tianjin Cancer Hospital Airport Hospital, Tianjin 300308, China.
- National Clinical Research Center for Cancer, Tianjin 300060, China.
- Haihe Laboratory of Synthetic Biology, Tianjin 300090, China.
Förderung
- National Natural Science Foundation of China
- Nankai University Eye Institute
- Natural Science Foundation of Tianjin
- Tianjin Key Medical Discipline (Specialty) Construction Project
Zitieren
APA
Zhang, K., Zhang, Y., Xiang, P., Wang, Y., Li, Y., Jiang, S., Zhang, Y., Chen, M., Su, W., Li, X., & Li, S. (2025). Advances in T Cell-Based Cancer Immunotherapy: From Fundamental Mechanisms to Clinical Prospects. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c01502
Vancouver
Zhang K, Zhang Y, Xiang P, Wang Y, Li Y, Jiang S, et al. Advances in T Cell-Based Cancer Immunotherapy: From Fundamental Mechanisms to Clinical Prospects. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.4c01502
BibTeX
@article{Zhang2025,
author = {Zhang, Kaili and Zhang, Yi and Xiang, Pan and Wang, Yi and Li, Yifan and Jiang, Shuze and Zhang, Yuxuan and Chen, Min and Su, Weijun and Li, Xiaoling and Li, Shuai},
title = {Advances in T Cell-Based Cancer Immunotherapy: From Fundamental Mechanisms to Clinical Prospects},
journal = {Molecular Pharmaceutics},
year = {2025},
doi = {10.1021/acs.molpharmaceut.4c01502}
}
EUVIMED